Dr. Khabele’s research laboratory uses a bi-directional translational research approach to develop novel drug combinations to treat ovarian cancer. Her lab group uses de-identified clinically annotated tissue samples and patient-derived xenograft models to validate molecular biomarkers and confirm mechanistic results for further testing in the clinic.
We utilize established cell-based and mouse models, functional genomics, transcriptomics, and proteomics to investigate the following focus areas:
- Epigenetic drug regimens for treating chemotherapy-resistant ovarian cancer
- Targeting macrophages in the ovarian tumor microenvironment